Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Risk Factors for Development of Brain Metastases
Author
Howard (Jack) West, MD

While brain metastases are common, some patients seem to be at higher risk than others. As previously noted, SCLC has a very high risk of spread to the brain. For NSCLC subtypes, several studies have shown that patients with non-squamous lung cancers have a greater tendency to develop brain metastases than those with squamous cancers, which tend toward more local spread. Here is the figure for development of brain metastases in patients treated for stage IIIA NSCLC out of the Harvard/Dana Farber system (abstract here).

Brain mets risk by histology (click to enlarge)

Another trial just published from UCSF evaluating the stage IIIA NSCLC population also found a high risk (55%) of recurrence in the brain after aggressive treatment, and that the risk of brain metastases was higher for patients with adenocarcinoma vs. squamous cell carcinoma (57% vs 34%, a statistically significant difference (abstract here)). The Boston study also demonstrated that patients who had a good response to pre-operative treatment (chemo, radiation, or a combination of both for all but 3 patient who had unsuspected N2 nodal disease at surgery) and cleared their mediastinal nodes at the time of subsequent surgery had significantly lower risk of developing brain metastases than patients who had N2 nodes positive at the time of surgery:

Brain met risk by mediastinal clearance

Finally, another trial out of Columbia in NYC was just published in the journal Radiology (abstract here), looking at the clinical variables that predicted for development of brain metastases among 264 patients with full imaging and clinical information available. Like the other studies, they reported that the patients with adenocarcinomas had a higher risk of developing brain metastases than those with squamous cell cancers, and the folks with undifferentiated cancers fall between them (likely actualy a mix of adenocarcinomas and squamous cell cancers). This study also reported that higher nodal stage predicts higher risk of developing brain metastases, and that the risk of brain metastases increased steadily as the size of the primary tumor increased, as shown here:

Brain met risk and tumor size

This study also reported that there was not an association of increased risk with being male or female, with patient age, or with location of the tumor being central or peripheral, toward the outer edge of the lung.

Practically speaking, this doesn't change our management. At this point, prophylatic cranial irradiation (PCI) is not a standard recommendation after potentially curative treatment for locally advanced NSCLC (topic reviewed in prior post), but with so many trials showing a high risk of "brain first" or "brain only" recurrence in this setting, it's a very important question. I routinely recommend that my patients who have undergone treatment for stage III NSCLC consider a clinical trial in this setting of PCI vs. observation here, because we don't know if it will be helpful or harmful or have no effect. I might be particularly inclined to recommend the trial in a patient with an adenocarcinoma, given the consistently higher risk of brain metastases seen in this population, but I recommend this trial for pretty much everyone. We need to see if there is a way to reduce the risk of brain metastases in both NSCLC and SCLC. There will be an important trial presented about PCI in extensive disease SCLC at our big international oncology meeting, ASCO, in early June, so I'll provide an update when the data are available. In the meantime, I'll continue the discussion with more on prognosis and management options in the coming posts.

Next Previous link

Previous PostNext Post

Related Content

Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.
Image
Terapias Dirigidas de Cancer de Pulmón 2024
Video
La Dra. Estelamari Rodríguez presenta información básica sobre el NSCLC EGFR+ y analiza la importancia de las pruebas de biomarcadores en el cáncer de pulmón y ofrece una descripción general de las opciones de tratamiento para la enfermedad EGFR+.  Para ver la playlist completa, de click aquí.        

Forum Discussions

Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...

Hi Bluebird,  Welcome to GRACE.  I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had. 

 

A CT would be...

Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...

Hi and welcome to GRACE.  I'm sorry to know you are entering a new stage.  I'm not about to comment just now but wanted to let you know I see your...

Edit to say, we can't give advice but we can comment with views and facts.  :)

 

My first thought is to ask if she has been seen at a large...

Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...

Recent Comments

JOIN THE CONVERSATION
Tagrix FDA Approval
By mariachristian on
Hi Judy! It is so good to…
By JanineT GRACE … on
Tagrix vs Tagrisso
By Dipakchavan on
Hello Linda, my name is…
By AlexandraGBeneke on